Podcast & Webinars

TWiPO #40 ~ ANR Meeting Recap & Understanding MYCN

July 1, 2014
TWiPO presents the first of a series of interviews from the Advances in Neuroblastoma Research meeting and co-hosts discuss how the discovery of the MYCN gene 30 years ago has helped scientists better understand neuroblastoma and impacted treatment options.

TWiPO #38 ~ Interview with John Goldberg

March 11, 2014
TWiPO guest Dr. John Goldberg explains about the challenges of phase I pediatric cancer clinical trials.

TWiPO #37 ~ Interview with Patrick Brown on Infant Leukemia

February 26, 2014
Patrick Brown, a featured guest on TWiPO, discusses the challenges of treating infant leukemia and conducting clinical trials in this patient population.

TWiPO #36 ~ Interview With Kathleen Neville

January 27, 2014
Kathleen Neville, a featured guest on TWiPO, and talks about the challenges of drug development in pediatric cancer with with host Dr. Tim Cripe.

TWiPO #35 ~ Interview with Robert Johnson

December 2, 2013
Robert Johnson, a featured guest on TWiPO, discusses his research on the third most common type of brain tumor in children, ependymomas.

TWiPO #34 ~Interview with Dr. Nancy Ratner

November 14, 2013
Nancy Ratner is a featured guest in this episode of TWiPO, and speaks with host Dr. Tim Cripe and co-host Dr. Robyn Dennis about her career and research in neurofibroma.

TWiPO #33 ~Effective Advocacy

October 31, 2013
Gavin Lindberg is a featured guest on TWiPO, with host Dr. Tim Cripe and co-host Dr. Robyn Dennis  about his work to increase funding for childhood cancer research.

TWiPO #32 ~ Ethics in Clinical Trials

October 18, 2013
In this episode, Dr. Eric Kodish speaks with host Dr. Tim Cripe and co-host Dr. Andy Kolb about informed consent and ethics surrounding childhood cancer clinical trials.

TWiPO #31 ~ Secondary Cancers in Cancer Survivors

October 3, 2013
Dr. Joseph Neglia (University of Minnesota) is nationally and internationally recognized for his contributions to the field of childhood cancer long-term effects. He idiscusses late effects and the risk of secondary cancers among childhood cancer survivors.